The neuroprotective effect of inflammation: Implications for the therapy of multiple sclerosis

Neurological Sciences

Volumn 27, Issue SUPPL. 1, 2006, Pages

  Hohlfeld, R ^a,b   Kerschensteiner, M ^a,b   Stadelmann, C ^c   Lassmann, H ^c   Wekerle, H ^a  

^a MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Immunomodulatory therapy; Multiple sclerosis; Neuroprotection; Neurotrophic factors

Indexed keywords

APOPTOSIS INHIBITOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CILIARY NEUROTROPHIC FACTOR; CYCLOSPORIN; GABAERGIC RECEPTOR AFFECTING AGENT; GLATIRAMER; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; LEUKEMIA INHIBITORY FACTOR; MINOCYCLINE; MYELIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEURITE PROMOTING FACTOR; NEUROPROTECTIVE AGENT; NEUROTROPHIC FACTOR; RAPAMYCIN; RILUZOLE; SCAVENGER; SODIUM CHANNEL BLOCKING AGENT; TACROLIMUS;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN SPECIFICITY; ARTICLE; CELL TYPE; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DRUG MECHANISM; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOREACTIVITY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY CELL; LEUKOENCEPHALOPATHY; MULTIPLE SCLEROSIS; NEUROIMMUNOLOGY; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN TRANSPORT; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; HUMANS; INFLAMMATION; MULTIPLE SCLEROSIS; NEUROPROTECTIVE AGENTS; T-LYMPHOCYTES;

EID: 33646791175     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10072-006-0537-7     Document Type: Article

References (35)

1. Kerschensteiner M, Stadelmann C, Dechant G et al (2003) Neurotrophic cross-talk between the nervous and immune systems: Implications for neurological diseases. Ann Neurol 53:292-304
2. Hohlfeld R, Kerschensteiner M, Stadelmann C et al (2000) The neuroprotective effect of inflammation: Implications for the therapy of multiple sclerosis. J Neuroimmunol 107:161-166
3. Moalem G, Leibowitz-Amit R, Yoles E et al (1999) Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nature Med 5:49-55
4. Schwartz M, Moalem G, Leibowitz-Amit R, Cohen IR (1999) Innate and adaptive immune responses can be beneficial for CNS repair. Trends Neurosci 22:295-299
5. Torcia M, Bracci-Laudiero L, Lucibello M et al (1996) Nerve growth factor is an autocrine survival factor for memory B lymphocytes. Cell 85:345-356
6. Kerschensteiner M, Gallmeier E, Behrens L et al (1999) Activated human T cells, B cells and monocytes produce brain-derived neurotrophic factor (BDNF) in vitro and in brain lesions: A neuroprotective role of inflammation? J Exp Med 189:865-870
7. Besser M, Wank R (1999) Clonally restricted production of the neurotrophins brain-derived neurotrophic factor and neurotrophin-3 mRNA by human immune cells and Th1/Th2-polarized expression of their receptors. J Immunol 162:6303-6306
8. Lewin GR, Barde YA (1996) Physiology of the neurotrophins. Annu Rev Neurosci 19:289-317
9. Cohen IR (1992) The cognitive paradigm and the immunological homunculus. Immunol Today 13:490-494
10. Linker RA, Mäurer M, Gaupp S et al (2002) CNTF is a major protective factor in demyelinating CNS disease: A neurotrophic cytokine as modulator in neuroinflammation. Nature Med 8:620-624
11. Butzkueven H, Zhang J-G, Soilu-Hänninen M et al (2002) LIF receptor signaling limits immune-mediated demyelination by enhancing oligodendrocyte survival. Nature Med 8:613-619
12. Giess R, Maurer M, Linker R et al (2002) Association of a null mutation in the CNTF gene with early onset of multiple sclerosis. Arch Neurol 59:407-409
13. Trapp BD, Peterson J, Ransohoff RM et al (1998) Axonal transection in the lesion of multiple sclerosis. N Engl J Med 338:278-285
14. Ferguson B, Matyszak MK, Esiri MM, Perry VH (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120:393-399
15. Kornek B, Lassmann H (1999) Axonal pathology in multiple sclerosis. A historical note. Brain Pathol 9:651-656
16. Neumann H, Medana IM, Bauer J, Lassmann H (2002) Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci 25:313-319
17. Babbe H, Roers A, Waisman A et al (2000) Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 192:393-404
18. + T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci USA 101:2428-2433
19. Jacobsen M, Cepok S, Quak E et al (2002) Oligoclonal expansion of memory CD8+ T cells in cerebrospinal fluid from multiple sclerosis patients. Brain 125:538-550
20. Lassmann H (2003) Axonal injury in multiple sclerosis. J Neurol Neurosurg Psych 74:695-697
21. Smith KJ, Lassmann H (2002) The role of nitric oxide in multiple sclerosis. Lancet Neurology 1:232-241
22. Aboul-Enein F, Rauschka H, Kornek B et al (2003) Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J Neuropathol Exp Neurol 62:25-33
23. Ziemssen T, Kumpfel T, Klinkert WEF et al (2002) Glatiramer acetate-specific T-helper 1-and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain 125:2381-2391
24. Kalkers NF, Barkhof F, Bergers E et al (2002) The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: A pilot study. Mult Scler 8:532-533
25. Guo X, Dillman JF, III, Dawson VL, Dawson TM (2001) Neuroimmunophilins: novel neuroprotective and neuroregenerative targets. Ann Neurol 50:6-16
26. Avramut M, Achim CL (2003) Immunophilins in nervous system degeneration and regeneration. Curr Top Med Chem 3:1376-1382
27. Brundula V, Rewcastle NB, Metz LM et al (2002) Targeting leukocyte MMPs and transmigration: Minocycline as a potential therapy for multiple sclerosis. Brain 125:1297-1308
28. Popovic N, Schubart A, Goetz BD et al (2002) Inhibition of autoimmune encephalomyelitis by a tetracycline. Ann Neurol 51:215-223
29. De Keyser J, Sulter G, Luiten PG (1999) Clinical trials with neuroprotective drugs in acute ischaemic stroke: Are we doing the right thing? Trends Neurosci 22:535-540
30. Hohlfeld R (1997) Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 120:865-916
31. Noseworthy JH, Gold R, Hartung HP (1999) Treatment of multiple sclerosis: Recent trial and future perspectives. Curr Opin Neurol 12:279-293
32. Hemmer B, Archelos JJ, Hartung HP (2002) New concepts in the immunopathogenesis of multiple sclerosis. Nature Rev Neurosci 3:291-301
33. Meinl E, Hoch RM, Dornmair K et al (1997) Encephalitogenic potential of myelin basic protein-specific T cells isolated from normal rhesus macaques. Am J Pathol 150:445-453
34. Kramer R, Zhang Y, Gehrmann J et al (1995) Gene transfer through the blood-nerve barrier: Nerve growth factor engineered neuritogenic T lymphocytes attenuate experimental autoimmune neuritis. Nature Med 1:1162-1166
35. + T lymphocytes: Green fluorescent protein engineered, encephalitogenic T cells used to illuminate immune responses in the brain. Nature Med 5:843-847